Early versus Late Pharmacologic Thromboprophylaxis in Traumatic Brain Injury: A Propensity-Score Matched Cohort Study
Frühe versus späte pharmakologische Thromboseprophylaxe bei traumatischem Hirntrauma: Propensity-Score-gepaarte Kohortenstudie
Seminars in Thrombosis and Hemostasis · 14.08.2026
DOI: 10.1055/a-2927-6855 ↗Auf einen Blick
Eine frühe Heparingabe (≤72 Stunden) war nach Propensity-Score-Matching mit weniger vaskulären Verschlussereignissen, geringerer Mortalität und kürzerem Krankenhausaufenthalt verbunden. Das Blutungsrisiko war nicht erhöht.
Fragestellung
Verringert eine frühe Heparingabe bei traumatischem Hirntrauma im Vergleich zu später Gabe (>72 Stunden) vaskuläre Verschlussereignisse, Mortalität und Aufenthaltsdauer ohne mehr Blutungen?
Methode
Propensity-Score-gepaarte Kohortenstudie mit Subgruppenanalysen und multivarianter logistischer Regression; Vergleich frühe vs. späte Heparingabe.
Ergebnisse
Nach Matching waren spätes Heparin mit mehr VOEs (25,16 % vs. 12,24 %; p<0,001), 30-Tage-Mortalität (20 % vs. 11,89 %; p=0,03), 180-Tage-Mortalität (32,26 % vs. 19,58 %; p=0,004) und längerer Hospitalisierung (Median 15,7 vs. 9,7 Tage; p<0,001) assoziiert; Blutung 16,77 % vs. 22,03 %; p=0,24. Bei mildem TBI war spätes Heparin ein unabhängiger Risikofaktor für VOEs: OR 2,62 (95 %-KI 1,54–4,45).
Schlussfolgerung der Autor:innen
Die Ergebnisse sprechen dafür, dass eine frühe Heparingabe thromboembolische Komplikationen, Mortalität und Aufenthaltsdauer senkt, ohne das Blutungsrisiko deutlich zu erhöhen.
Kernaussagen
- Frühes Heparin: weniger VOEs als spätes Heparin
- Auch 30- und 180-Tage-Mortalität niedriger
- Kein signifikanter Anstieg von Blutungen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 14.08.2026. Verfasst von Wei Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Xi'an Jiaotong University, Shaanxi, China, Xi'an. Gefördert von: Shaanxi Provincial Postdoctoral Fellowship, Natural Science Foundation of Shaanxi Province, Natural Science Basic Research Program of Shaanxi Province.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
AbstractThe optimal timing of pharmacological thromboprophylaxis in traumatic brain injury (TBI) remains uncertain due to competing risks of thrombosis and bleeding. This study evaluated whether early heparin initiation (≤72 hours) reduces vascular occlusive events (VOEs), mortality, and hospital stay without increasing bleeding. We compared early versus late (>72 hours) heparin use via propensity score matching (PSM), subgroup analyses, and multivariable logistic regression. Outcomes included VOEs (deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke), bleeding, 30- and 180-day mortality, and length of stay. After PSM, late heparin was associated with higher VOEs (25.16 vs. 12.24%, p < 0.001), 30-day mortality (20 vs. 11.89%, p = 0.03), 180-day mortality (32.26 vs. 19.58%, p = 0.004), and prolonged hospitalization (median: 15.7 vs. 9.7 days, p < 0.001), without increased bleeding risk (16.77 vs. 22.03%, p = 0.24). Subgroup analyses revealed late heparin as an independent risk factor for VOEs in mild TBI (odds ratio: 2.62, 95% confidence interval: 1.54–4.45; p < 0.001) regardless of fracture status, coagulation profile, or hemorrhagic classification, with nonsignificant associations in nonhemorrhagic and moderate-to-severe TBI subgroups. Multivariable analysis identified late heparin, higher comorbidity index, elevated platelet count, and cranial surgery as independent predictors of VOEs, with late heparin also independently associated with increased mortality. These findings suggest early heparin initiation reduces thromboembolic complications, mortality, and hospital stay without markedly increasing bleeding risk, supporting early anticoagulation in selected patients following individualized risk-benefit assessment.
Autor:innen und Institutionen
- Xi'an Jiaotong University, Shaanxi, China, Xi'an.
- The Second Hospital of Dalian Medical University, Department of Clinical Laboratory, Liaoning, China, Dalian.
- Faculty of Medicine, Benha University, Department of Orthopaedic Surgery, Egypt, Banha.
- Shanghai Jiao Tong University School of Medicine, Shanghai General Hospital, Department of Neurosurgery, China, Shanghai.
- Xi'an Jiaotong University School of Life Science and Technology, The Key Laboratory of Biomedical Information Engineering, Ministry of Education, Department of Biomedical Engineering, Shaanxi, China, Xi'an.
- The First Affiliated Hospital of Xi'an Jiaotong University, PET-CT Center, Shaanxi, China, Xi'an.
ORCID-Profile: Wei Jiang, Lianwei Ma, Xiang Wu, Lijun Bai, Zhuonan Wang
Förderung
- Shaanxi Provincial Postdoctoral Fellowship
- Natural Science Foundation of Shaanxi Province
- Natural Science Basic Research Program of Shaanxi Province
- Clinical Technology Improvement Project of the Second Hospital of Dalian Medical University
- National Key Research and Development Program of China
- Key Research and Development Project of the Shaanxi Provincial Health Science and Technology Innovation Capacity Enhancement Program
Zitieren
APA
Jiang, W., Ma, L., Elashhab, M. G. E. A. E. H., Wu, X., Bai, L., & Wang, Z. (2026). Early versus Late Pharmacologic Thromboprophylaxis in Traumatic Brain Injury: A Propensity-Score Matched Cohort Study. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2927-6855
Vancouver
Jiang W, Ma L, Elashhab MGEAEH, Wu X, Bai L, Wang Z. Early versus Late Pharmacologic Thromboprophylaxis in Traumatic Brain Injury: A Propensity-Score Matched Cohort Study. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2927-6855
BibTeX
@article{Jiang2026,
author = {Jiang, Wei and Ma, Lianwei and Elashhab, Mohamed Gamal Eldin Abd El Hamid and Wu, Xiang and Bai, Lijun and Wang, Zhuonan},
title = {Early versus Late Pharmacologic Thromboprophylaxis in Traumatic Brain Injury: A Propensity-Score Matched Cohort Study},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
doi = {10.1055/a-2927-6855}
}
EUVIMED